Does mycophenolic acid inhibit IMPDH and suppress lymphocyte proliferation?

Mycophenolic acid (MPA), the active immunosuppressive metabolite of mycophenolate formulations, acts through a well-established nucleotide-metabolism mechanism that preferentially constrains proliferation of activated lymphocytes.

Mechanistic and pharmacodynamic evidence

• MPA reversibly inhibits inosine monophosphate dehydrogenase (IMPDH), with preferential activity toward the activation-associated IMPDH2 isoform. IMPDH catalyzes the IMP-to-XMP step required for de novo production of GMP and its downstream guanosine nucleotides (GDP, GTP, and dGTP).
• Human pharmacodynamic findings demonstrate target engagement: peripheral-blood mononuclear-cell and whole-blood IMPDH activity varies inversely with MPA concentration. In CD4-positive cells, the pooled EC50 for inhibition was approximately 2.3 mg/L, with near-plateau inhibition at clinically relevant exposures.
• In human PBMCs, 5 µM MPA reduced intracellular GTP to 56% of control; guanosine restored GTP, directly linking the effect to impaired de novo guanosine-nucleotide synthesis.

Lymphocyte effects and clinical relevance

• Activated T and B cells rely substantially on de novo purine synthesis during clonal expansion. MPA-associated depletion of GMP/GTP, particularly dGTP needed for DNA replication, causes cell-cycle restraint and diminished mitogen- or alloantigen-induced proliferation.
• Approximately 1 µM MPA induced G1 arrest in human T lymphocytes, reversed by guanosine repletion. This rescue supports nucleotide depletion—not nonspecific cytotoxicity—as the proximate cause.
• The mechanism aligns with transplant efficacy: adding mycophenolate mofetil to cyclosporine and corticosteroids reduced one-year biopsy-proven acute rejection or treatment failure from 56.0% with placebo to 30.3–38.8% (P<0.001). Versus azathioprine, acute rejection was lower (RR 0.62, 95% CI 0.55–0.87).

Bottom line

• The claim is strongly supported: MPA inhibits IMPDH, lowers de novo guanosine nucleotide availability, and thereby suppresses activated lymphocyte proliferation. This therapeutic immunosuppression also explains clinically important risks including leukopenia, gastrointestinal effects, and opportunistic infection.